U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C10H21N.ClH
Molecular Weight 191.741
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROPYLHEXEDRINE HYDROCHLORIDE

SMILES

Cl.CNC(C)CC1CCCCC1

InChI

InChIKey=WLEGHNSHAIHZPS-UHFFFAOYSA-N
InChI=1S/C10H21N.ClH/c1-9(11-2)8-10-6-4-3-5-7-10;/h9-11H,3-8H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula C10H21N
Molecular Weight 155.2804
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Propylhexedrine is considered to be an agonist of alpha-adrenergic receptors. It is effective as a topical vasoconstrictor. The primary medicinal use of Benzedrex (Propylhexedrine inhaler) propylhexedrine is temporary symptomatic relief of nasal decongestion due to colds, allergies and allergic rhinitis. Structurally and pharmacologically related to amphetamine.Exact mechanism of action unknown but thought to be similar to amphetamine. When used as a nasal inhaler for this indication, propylhexedrine reduces nasal airway resistance without producing rebound congestion. Abuse does not occur by nasal inhalation; however, a small amount of abuse of the propylhexedrine containing nasal inhalers occurs by oral ingestion of the contents of the inhaler or by intravenous injection. Propylhexedrine is a central nervous system (CNS) stimulant of low abuse potential, a stimulant of low preference for stimulant abusers compared with amphetamine, methylphenidate, phenmetrazine.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Benzedrex

Approved Use

Self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other allergies. Reduce swelling and facilitate visualization of nasal and pharyngeal membranes prior to surgery or diagnostic procedures. Open obstructed eustachian ostia in patients with ear inflammation.

Launch Date

1948
PubMed

PubMed

TitleDatePubMed
The pharmacologic activity of N-methyl-beta-cyclohexyl-isopropylamine hydrochloride.
1947 Apr
Nasal decongestant effect of propylhexedrine.
1982 Jan-Feb
Propylhexdrine.
1986 Jun
Propylhexedrine: a vintage drug of abuse, rediscovered.
2012 Jul-Aug
Patents

Patents

Sample Use Guides

The Benzedrex propylhexedrine inhaler delivers 0.4–0.5 mg of the drug in each 800 mL of air. Adult dosage: 2 inhalations (0.4–0.5 mg) in each nostril no more than every 2 hours.
Route of Administration: Nasal
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:15:45 GMT 2023
Edited
by admin
on Fri Dec 15 15:15:45 GMT 2023
Record UNII
064LUN7NZ5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROPYLHEXEDRINE HYDROCHLORIDE
MART.  
Common Name English
EVENTIN HYDROCHLORIDE
Brand Name English
PROPYLHEXEDRINE HYDROCHLORIDE [MART.]
Common Name English
DL-PROPYLHEXEDRINE HYDROCHLORIDE
Common Name English
(RS)-N,.ALPHA.-DIMETHYL-CYCLOHEXYLETHYLAMINE HYDROCHLORIDE
Systematic Name English
CYCLOHEXYL(ISOPROPYL)METHYLAMMONIUM CHLORIDE
Systematic Name English
NSC-27110
Code English
BENZEDREX HYDROCHLORIDE
Brand Name English
(±)-PROPYLHEXEDRINE HYDROCHLORIDE
Common Name English
NSC-170998
Code English
PROPYLHEXEDRINE DL-FORM HYDROCHLORIDE [MI]
Common Name English
CYCLOHEXANEETHANAMINE, N,.ALPHA.-DIMETHYL-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
102541
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY
MERCK INDEX
m9242
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY Merck Index
RXCUI
236461
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
213-753-7
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY
NSC
27110
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY
MESH
C084814
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID70873945
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY
FDA UNII
064LUN7NZ5
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY
CAS
1007-33-6
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY
CAS
6192-95-6
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
SUPERSEDED
NSC
170998
Created by admin on Fri Dec 15 15:15:45 GMT 2023 , Edited by admin on Fri Dec 15 15:15:45 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY